Media

  • Berwyn-Based Pharmaceutical Company Takes Over-the-Counter Route for Approval of Its New Drug Candidate

    Jul 28, 2022

  • Chester County pharma firm pivots to OTC strategy for experimental pain drug

    Jun 27, 2022

  • Virpax selects Kindeva Drug Delivery as development partner for Diclofenac pMDI commercialization

    Apr 27, 2022

  • [VIDEO] Virpax appears on 6abc Philadelphia

    Mar 29, 2022

  • Virpax shares rise on expanded licensing deal for experimental drug

    Mar 15, 2022

  • ThinkEquity Initiates Coverage on Virpax Pharmaceuticals

    Mar 4, 2022

  • Opiate Alternative: As the US opioid crisis continues, there is now significant interest in non-addictive painkillers

    Feb 23, 2022

  • NIH-backed nasal nonaddictive pain prospect clears early test

    Feb 15, 2022

  • Altasciences chosen by Virpax to conduct first-in-human study of Epoladerm™ for chronic pain associated with osteoarthritis of the knee

    Jan 21, 2022

  • Virpax to start clinical trial for knee pain drug candidate

    Dec 23, 2021

  • How Pharma and Academia are Tackling the Opioid Epidemic

    Dec 17, 2021

  • New CBD nasal spray to target seizures in epilepsy

    Dec 9, 2021

  • Virpax to Develop CBD Nasal Spray for Epilepsy

    Dec 7, 2021

  • Pain Management Company Virpax Sees Promise in Potential COVID-19 Antiviral OTC

    Nov 17, 2021

  • Chester County drug developer Virpax working on ‘molecular mask’ to combat Covid-19

    Sep 4, 2020

  • Is Biopharma Still Committed To Its Role In Public Health?

    Dec 3, 2018

Recent Press Releases

Read the latest investor news about Virpax.

View all